

WR-033-94

AD-A279 920

NTATION PAGE

Form Approved  
OMB No 0704-0188

Not to exceed 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering the collection of information, sending comments regarding this burden estimate or any other aspect of this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Drive, Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20543

1. DATE

3. REPORT TYPE AND DATES COVERED

## 4. TITLE AND SUBTITLE

Corticotropin-releasing factor increased  $[Ca^{2+}]_i$  via receptor-mediated  $Ca^{2+}$  channels in human epidermoid A-431 cells

## 5. FUNDING NUMBERS

WIDN

## 6. AUTHOR(S)

Juliann G. Kiang

## 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Walter Reed Army Institute of Research  
Washington, DC 20307-5100

## 8. PERFORMING ORGANIZATION REPORT NUMBER

## 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)

US Army Medical Research & Development Command  
Ft. Detrick, Frederick, MD 21702-5012

## 10. SPONSORING/MONITORING AGENCY REPORT NUMBER

## 11. SUPPLEMENTARY NOTES

DTIC  
ELECTE  
JUN 02 1994  
S G D

## 12a. DISTRIBUTION/AVAILABILITY STATEMENT

APPROVED FOR PUBLIC RELEASE:  
DISTRIBUTION UNLIMITED

## 12b. DISTRIBUTION CODE

## 13. ABSTRACT (Maximum 200 words)

Corticotropin-releasing factor (CRF) has been shown to attenuate vascular leakage in injured skin, mucous membrane, muscle, and brain. Calcium is thought to play an important role in many of the physiological responses to CRF, but there has been little characterization of how calcium is involved in process by which CRF protects damaged tissues. The goal of this study was to characterize changes in cytosolic free calcium concentrations ( $[Ca^{2+}]_i$ ) in human epidermoid A-431 cells exposed to human/rat-CRF and to investigate the mechanisms by which these changes occur. The resting  $[Ca^{2+}]_i$  in normal cells at 37°C was  $66 \pm 4$  nM ( $n = 32$ ). When cells were treated with CRF,  $[Ca^{2+}]_i$  increased immediately. The increase depended on CRF concentration, with a median effective concentration of 11 pM. This increase in  $[Ca^{2+}]_i$  depended on external  $Ca^{2+}$  but not  $Na^+$ ,  $Mg^{2+}$ , or  $K^+$ .  $La^{3+}$  (10  $\mu$ M) and  $Co^{2+}$  (10  $\mu$ M) inhibited the CRF-induced  $[Ca^{2+}]_i$  increase, whereas verapamil and nifedipine tested at concentrations up to 1 mM did not.  $\alpha$ -Helical CRF-(9-41), a synthetic CRF receptor antagonist, and pertussis toxin blocked the increase in  $[Ca^{2+}]_i$  induced by CRF, which suggests that the entry of extracellular  $Ca^{2+}$  is mediated by receptor-operated  $Ca^{2+}$  channels coupled with pertussis toxin-sensitive G proteins. Although 420 pM CRF stimulated an immediate increase in  $[Ca^{2+}]_i$ , inositol triphosphate and cellular cAMP levels did not change within 1 min either in the presence or absence of external  $Ca^{2+}$ . U-73122 (an inhibitor of inositol triphosphate production), amiloride and benzamil (inhibitors of the  $Na^+/Ca^{2+}$  exchanger) also did not block the increase in  $[Ca^{2+}]_i$  induced by CRF. CRF also increased  $[Ca^{2+}]_i$  in cells treated with TMB-8 or ryanodine, inhibitors of intracellular  $Ca^{2+}$  mobilization. The results suggest that CRF stimulates a  $Ca^{2+}$  influx through CRF receptor-operated  $Ca^{2+}$  channels.

## 14. SUBJECT TERMS

$Ca^{2+}$ ; Corticotropin-releasing factor,  $Ca^{2+}$  channel; Pertussis toxin; Epithelium

## 15. NUMBER OF PAGES

## 16. PRICE CODE

## 17. SECURITY CLASSIFICATION OF REPORT

## 18. SECURITY CLASSIFICATION OF THIS PAGE

## 19. SECURITY CLASSIFICATION OF ABSTRACT

## 20. LIMITATION OF ABSTRACT

Reprinted from

# European Journal of Pharmacology

European Journal of Pharmacology  
Molecular Pharmacology Section 267 (1994) 135-142

Corticotropin-releasing factor increases  $[Ca^{2+}]_i$  via receptor-mediated  $Ca^{2+}$  channels in human epidermoid A-431 cells

Juliann G. Kiang

Department of Clinical Physiology, Division of Medicine, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA

(Received 28 April 1993; revised MS received 13 September 1993; accepted 16 November 1993)

Accession For	
NTIS	CRA&I <input checked="" type="checkbox"/>
DTIC	TAB <input type="checkbox"/>
Unannounced <input type="checkbox"/>	
Justification .....	
By .....	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	20

THIS QUANTITY INSPECTED 2

94-16318  
1198



94 6 1 060

# European Journal of Pharmacology

## Molecular Pharmacology Section

The EUROPEAN JOURNAL OF PHARMACOLOGY (MOLECULAR PHARMACOLOGY SECTION) publishes manuscripts on the interactions at the molecular level of substances with biological systems.

Manuscripts submitted to the journal are only accepted on the understanding that: (1) they are subject to editorial review; (2) they have not been and will not be published in whole or in part in any other journal; (3) the recommendations from the declaration of Helsinki and the internationally accepted principles in the care and use of experimental animals have been adhered to.

In addition to full length papers, the journal publishes short communications, rapid communications and commissioned short articles intended to debate recent advances in rapidly developing fields. Acceptability of rapid communications will be decided by the editors of the journal, who will be advised by an external referee. Full length manuscripts and short communications are generally submitted to 2 referees who are chosen for their ability to evaluate the work. Authors may request that certain referees should not be chosen. Members of the editorial board will usually be called upon for advice when there is disagreement among the referees or between referees and authors, or when the editors believe that the manuscript has not received adequate consideration from the referees. In order to reduce mailing cost, manuscripts will not be returned. Only the decision of the editorial office, together with the advice of the referees will be sent to the author(s). Referees will be requested to keep the copy of the manuscript which they have received for evaluation, and to destroy it once they have been notified of the final decision concerning the manuscript. When authors submit a revised manuscript, they should reply to the comments of the referees, indicating which comments have been incorporated and the reasons for disregarding any suggestions considered unacceptable. Revised manuscripts should be returned in duplicate to the editors. A revised manuscript should be received by the editorial office not later than 5 weeks (in case of minor revision) or 10 weeks (in case of extensive revision) after the editorial decision was sent to the author(s); otherwise it will be processed as a new manuscript. Handwritten additions or corrections will not be accepted. Only complete retyping of the pages affected by revision is acceptable.

For further information please refer to the 'General instructions' at the end of this issue, and the 'Notice to authors' published in Vol. 266, No. 1, p. v.

**Editors:** J. BRUINVELS, Utrecht      W.H. GISPEN, Utrecht      D.H.G. VERSTEEG, Utrecht

### Editorial Board:

K. AKTORIES, Homburg  
E.A. BARNARD, London  
J. BOCKAERT, Montpellier  
F. CATTABENI, Milan  
P.R. DUNKLEY, Newcastle  
B.B. FREDHOLM, Stockholm  
H. GLOSSMANN, Innsbruck  
M. HAMON, Paris  
M.D. HOLLENBERG, Calgary  
D. HOYER, Basel  
E.C. HULME, London  
K.H. JAKOBS, Essen  
M. LAZDUNSKI, Valbonne  
J.E. LEYSEN, Beerse  
B.G. LIVETT, Parkville  
R.J. MILLER, Chicago

K.P. MINNEMAN, Atlanta  
F. MORONI, Florence  
S. NAHORSKI, Leicester  
D.G. NICHOLLS, Dundee  
M. NIELSEN, Roskilde  
P. RIEDERER, Würzburg  
Y. SALOMON, Rehovot  
W. SCHLEGEL, Genève  
P. SKOLNICK, Bethesda  
S.H. SNYDER, Baltimore  
M. SOKOLOVSKY, Tel Aviv  
M.J. SOLE, Toronto  
W. SOUDIJN, Leiden  
C. TANAKA, Kobe  
J. TRABER, Köln  
J. ZAAGSMA, Groningen

### Consultants:

I. CREESE, Newark; S.K. FISHER, Ann Arbor; J.A. GARCÍA-SÁINZ, Mexico; P.D. HRDINA, Ottawa; J.P. PIN, San Diego; M. RAITERI, Genova; P.J. ROBERTS, Southampton; J.C. STOOF, Amsterdam; D.J. TRIGGLE, Buffalo

## Corticotropin-releasing factor increases $[Ca^{2+}]_i$ via receptor-mediated $Ca^{2+}$ channels in human epidermoid A-431 cells

Juliann G. Kiang

Department of Clinical Physiology, Division of Medicine, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA

(Received 28 April 1993; revised MS received 13 September 1993; accepted 16 November 1993)

### Abstract

Corticotropin-releasing factor (CRF) has been shown to attenuate vascular leakage in injured skin, mucous membrane, muscle, and brain. Calcium is thought to play an important role in many of the physiological responses to CRF, but there has been little characterization of how calcium is involved in process by which CRF protects damaged tissues. The goal of this study was to characterize changes in cytosolic free calcium concentrations ( $[Ca^{2+}]_i$ ) in human epidermoid A-431 cells exposed to human/rat-CRF and to investigate the mechanisms by which these changes occur. The resting  $[Ca^{2+}]_i$  in normal cells at 37°C was  $66 \pm 4$  nM ( $n = 32$ ). When cells were treated with CRF,  $[Ca^{2+}]_i$  increased immediately. The increase depended on CRF concentration, with a median effective concentration of 11 pM. This increase in  $[Ca^{2+}]_i$  depended on external  $Ca^{2+}$  but not  $Na^+$ ,  $Mg^{2+}$ , or  $K^+$ .  $La^{3+}$  (10  $\mu$ M) and  $Co^{2+}$  (10  $\mu$ M) inhibited the CRF-induced  $[Ca^{2+}]_i$  increase, whereas verapamil and nifedipine tested at concentrations up to 1 mM did not.  $\alpha$ -Helical CRF-(9–41), a synthetic CRF receptor antagonist, and pertussis toxin blocked the increase in  $[Ca^{2+}]_i$  induced by CRF, which suggests that the entry of extracellular  $Ca^{2+}$  is mediated by receptor-operated  $Ca^{2+}$  channels coupled with pertussis toxin-sensitive G proteins. Although 420 pM CRF stimulated an immediate increase in  $[Ca^{2+}]_i$ , inositol trisphosphate and cellular cAMP levels did not change within 1 min either in the presence or absence of external  $Ca^{2+}$ . U-73122 (an inhibitor of inositol trisphosphate production), amiloride and benzamil (inhibitors of the  $Na^+/Ca^{2+}$  exchanger) also did not block the increase in  $[Ca^{2+}]_i$  induced by CRF. CRF also increased  $[Ca^{2+}]_i$  in cells treated with TMB-8 or ryanodine, inhibitors of intracellular  $Ca^{2+}$  mobilization. The results suggest that CRF stimulates a  $Ca^{2+}$  influx through CRF receptor-operated  $Ca^{2+}$  channels.

**Key words:**  $Ca^{2+}$ ; Corticotropin-releasing factor;  $Ca^{2+}$  channel; Pertussis toxin; Epithelium

### 1. Introduction

The endocrine function of corticotropin-releasing factor (CRF) to stimulate adrenocorticotropin (ACTH) release is well-characterized, and its distribution throughout the body has been demonstrated. Using immunohistological techniques, CRF-like substances have been detected in many systemic organs including liver, spleen, pancreas, stomach, duodenum, and adrenal medulla (Petrusz et al., 1984). CRF is also present in hypothalamus and other parts of brain (Merchenthaler, 1984). The CRF levels in hypophyseal portal blood and systemic plasma in human are 400 and 75 pg/ml, respectively (Plotsky, 1985). CRF is

present in the final stages of human pregnancy at a level about 20 times the normal level (Linton et al., 1990a,b; Wolfe et al., 1988).

The exposure of tissues to exogenous CRF produces a variety of effects, including a decreased heart rate and blood pressure (Kiang and Wei, 1986) and a reduction in the detrimental effects of several kinds of injuries (Kiang and Wei, 1987; Wei and Kiang, 1987; Wei et al., 1988; Serda and Wei, 1991, 1992; Wei and Gao, 1991).

The mechanism by which CRF reduces the edema and protein extravasation characteristic of such injuries is not known. It is possible that changes in cytosolic free calcium ( $[Ca^{2+}]_i$ ) play an essential role in CRF protection because other CRF actions have been shown to involve  $Ca^{2+}$ . For example, in human ACTH-secreting pituitary adenoma cells and normal rat small ovoid

\* Tel.: (202) 576-3098; Fax: (202) 576-0703.

corticotrophs, Guerinéau et al. (1991) found that 100 nM CRF increased  $[Ca^{2+}]_i$  by opening both L- and T-type voltage-gated  $Ca^{2+}$  channels. In corticotroph-derived AtT-20 cells, the CRF-induced increase in *c-fos* mRNA is reduced by blocking  $Ca^{2+}$  entry or by treatment with calmodulin inhibitors (Boutillier et al., 1991). Furthermore, ACTH release stimulated by CRF is reduced in the absence of external  $Ca^{2+}$ , by depletion of intracellular  $Ca^{2+}$  stores, or by treatment with calmodulin inhibitors (Won and Orth, 1990).

It has been shown that the epidermal necrosis produced by heat injury in rat paw skin (Wei et al., 1987) and human epidermoid A-431 cells (Kiang et al., 1988), a non-endocrine cell line, is reduced by pretreatment with CRF. Because  $Ca^{2+}$  homeostasis in A-431 cells has been extensively described (Kiang, 1991; Kiang et al., 1992), we used these cells to characterize the effect of CRF on  $[Ca^{2+}]_i$  and investigate the underlying mechanisms of action. The results of our experiments show that CRF treatment caused an increase in  $[Ca^{2+}]_i$  that was antagonized by  $\alpha$ -helical CRF-(9–41), a CRF receptor antagonist.

## 2. Materials and methods

### 2.1. Cell culture

Human epidermoid carcinoma A-431 cells (American Type Culture Collection, Rockville, MD) were grown on glass cover slips (9 × 35 mm, Clay Adams, Lincoln Park, NJ) incubated at 37°C in a 5%  $CO_2$  atmosphere. The tissue culture medium was Dulbecco's modified Eagle medium supplemented with 0.03% glutamine, 4.5 g/l glucose, 25 mM Hepes, 10% fetal bovine serum, 50  $\mu$ g/ml penicillin, and 50 U/ml streptomycin (Gibco Laboratories, Grand Island, NY). Cells were fed every 3–4 days. Cells from passage 28–45 were used for experiments.

### 2.2. Measurements

#### *Intracellular $Ca^{2+}$ measurements*

Confluent monolayers of cells were loaded with 5  $\mu$ M fura-2AM plus 0.2% pluronic F-127 (to make cells more permeable to the probe) at 37°C for 60 min. Cells were washed with  $Na^+$  Hanks' solution (in mM: 145 NaCl, 4.6 KCl, 1.2  $MgCl_2$ , 1.6  $CaCl_2$ , and 10 HEPES, pH 7.4 at 24°C) before fluorescence measurements. The method to determine  $[Ca^{2+}]_i$  has been described previously (Grynkiewicz et al., 1985; Kiang, 1991). Briefly, the confluent monolayer of cells was placed in a thermostatically controlled cuvette that was kept at a constant temperature of 37°C. The fluorescence signal was measured with the emission wavelength set at 510 nm and dual excitation at 340 nm and 380 nm (slit

width 4 nm) with a PTI DeltaScan spectrofluorometer (Photon Technology International, South Brunswick, NJ). Autofluorescence from cells not loaded with the dye was in the range of 3000–4000 photons/s and was subtracted from the fura-2 signal. Fura-2 leaked out of A-431 cells at a rate of  $0.38 \pm 0.01\%$ /min ( $n = 3$ ) at 37°C. To minimize any contribution to the fluorescence signal resulting from dye in the medium, cells were washed thoroughly in Hanks' solution before they were transferred to a cuvette to measure  $[Ca^{2+}]_i$ .  $[Ca^{2+}]_i$  was calculated according to the method of Grynkiewicz et al. (1985).

#### *Inositol trisphosphates measurements*

Inositol trisphosphates ( $InsP_3$ ) were measured as described by Berridge (1983) and my laboratory (Kiang and McClain, 1993). In brief, cells were grown in 6-well plates and incubated with *myo*- $[^3H]$ inositol (2  $\mu$ Ci/ml, 0.22 nmol/ml, Dupont/NEN, Boston, MA) for 24 h. Cells were washed twice with  $Na^+$  Hanks' solution then incubated with CRF for 5 s, 1, 5, or 10 min. The reaction was stopped by adding 3 ml ice-cold 4.5%  $HClO_4:Na^+$  Hanks' solution (2:1, v/v). Each plate was placed on ice for 30 min, and the cells were removed by scraping. Cells were pelleted by centrifugation (750 ×  $g$ ) and the supernatants were collected. The pH of the supernatants was adjusted to pH 8.0 with KOH before storing at  $-70^\circ C$ . An aliquot (100  $\mu$ l) of supernatant, which contained all of the  $[^3H]$ inositol and  $[^3H]$ polyphosphoinositol metabolites, was counted to determine total radioactivity in the cells.  $[^3H]InsP_3$  was eluted by 100 mM formic acid in 1.0 M ammonium formate (38 ml) from a Dowex AG 1- $\times$ 8 resin column. Radioactivity was determined by mixing 1 ml of the eluent with 10 ml of aquasol scintillation cocktail and counted with a scintillation counter. The amount of  $InsP_3$  was then expressed as a percentage of total counts per minute in each well.

#### *cAMP measurements*

Confluent monolayers of cells ( $2 \times 10^6$ /35 mm culture dish) were washed twice with PBS before incubating with PBS for 1 h at 37°C. Incubation was then continued with 3-isobutyl-1-methylxanthine (IBMX, final concentration 1 mM) for 30 min at 37°C, after which the medium was removed.  $Na^+$  Hanks' solution containing CRF was added into the culture dish for 5 s, 1, 5 or 10 min. The medium was discarded, and 1 ml of 0.1 M HCl was added to each culture dish to stop the reaction by killing the cells. The culture dishes were maintained at 4°C for 1–2 h before transferring the suspensions to test tubes. The samples were boiled for 10 min and the precipitates removed by centrifugation at 2000 ×  $g$  for 10 min. The supernatants were stored at  $-20^\circ C$  until the cAMP measurement.

cAMP was determined by radioimmunoassay using the method of Lin et al. (1985). Briefly, the procedure was as follows. Samples or standards (5 to 2000 fmol/tube) in 25 to 100  $\mu$ l were made up to 200  $\mu$ l with 50 mM acetate buffer, pH 6.2, and acetylated with 5  $\mu$ l acetic anhydride:triethylamine (1:2, v/v). After 15 min at room temperature, [ $^{125}$ I]succinyl cAMP antiserum, sufficient to bind 30–60% of the radioactive ligand, was added. After 4 h at room temperature, rabbit serum carrier and the second antiserum (anti-rabbit Ig from sheep, goat, or burro, Meloy Labs) were added. After standing overnight at 4°C, 2 ml of cold 10 mM acetate buffer, pH 6.2, was added, the tubes were centrifuged, and the radioactivity in the pellets counted. Each sample was measured in duplicate.

### 2.3. Statistical analysis

All data are expressed as mean  $\pm$  S.E.M. Analysis of variance, Bonferroni's inequality, and Student's *t*-test were used for comparison of groups. Curve fitting was determined using the Inplot program (GraphPad, San Diego, CA).

### 2.4. Chemicals

Corticotropin-releasing factor (human/rat) and  $\alpha$ -helical CRF-(9–41) were purchased from Peninsula Laboratories (Belmont, CA). Other chemicals used in this study were fura-2/AM, pluronic acid F-127, 8-(diethylamino)octyl 3,4,5-trimethoxybenzoate (TMB-8, Molecular Probes, Eugene, OR), benzamil (Research Biochemicals, Natick, MA), amiloride, verapamil HCl,  $\text{LaCl}_3$ ,  $\text{CoCl}_2$ , pertussis toxin, suramin, (+)-*N*-methylglucamine, ryanodine, IBMX (Sigma Chemicals, St. Louis, MO). 1-[6-[(17 $\beta$ -3-methoxyestra-1,3,5(10)-trien-17-yl)amino]hexyl]-1*H*-tyrrole-2,5-dione (U-73122) was provided by Upjohn Co. (Kalamazoo, MI). Naloxone was a gift from Dr. Brian Cox.

## 3. Results

### 3.1. Effect of CRF on $[\text{Ca}^{2+}]_i$

The resting  $[\text{Ca}^{2+}]_i$  in adherent cells at 37°C in normal  $\text{Na}^+$  Hanks' solution was  $66 \pm 4$  nM ( $n = 32$ ). When cells were treated with CRF, there was an immediate increase (within 10 s) in  $[\text{Ca}^{2+}]_i$  dependent on the concentration of CRF (Fig. 1A). The median effective concentration ( $\text{EC}_{50}$ ) of CRF was 11 pM. A concentration of 42 pM induced a maximal increase in  $[\text{Ca}^{2+}]_i$  ( $237 \pm 20\%$  control,  $n = 10$ ) (Fig. 1B). The increase induced by CRF was dependent on the presence of external  $\text{Ca}^{2+}$ . In  $\text{Ca}^{2+}$ -free buffer containing 10 mM EGTA, the CRF-induced increase in  $[\text{Ca}^{2+}]_i$  was




Fig. 1. CRF increases  $[\text{Ca}^{2+}]_i$ . Cells were treated with CRF at different concentrations ( $n = 3-4$ ). The fluorometer tracing (A) and a sigmoid-curved fit (B) are presented. The calculated median effective concentration was 11 pM.

not observed (Figs. 2 and 3). When increasing concentrations of  $\text{Ca}^{2+}$  were added back to the buffer,  $[\text{Ca}^{2+}]_i$  increased proportionally, suggesting that the CRF-induced increase in  $[\text{Ca}^{2+}]_i$  is a result of  $\text{Ca}^{2+}$  entry from external sources. When cells were incubated in a buffer without  $\text{Na}^+$  (replaced with equimolar (+)-*N*-methylglucamine) or  $\text{Mg}^{2+}$ , the resting  $[\text{Ca}^{2+}]_i$  increased significantly. Removal of external  $\text{Na}^+$  activates the




Fig. 2. Effect of external  $\text{Ca}^{2+}$  ( $[\text{Ca}^{2+}]_o$ ) on the CRF-induced increase in  $[\text{Ca}^{2+}]_i$ . Cells were exposed to 42 pM CRF in  $\text{Na}^+$  Hanks' solution containing different  $[\text{Ca}^{2+}]_o$  ( $n = 3-6$ ). \*  $P < 0.05$  vs. 0 external  $\text{Ca}^{2+}$ .




Fig. 3. Effect of external ions on CRF-induced increase in  $[Ca^{2+}]_i$ . The control buffer contained in mM 145 NaCl, 4.5 KCl, 1.3  $MgCl_2$ , 1.6  $CaCl_2$ , and 5 HEPES. The  $Ca^{2+}$ -free buffer contained 10 mM EGTA without  $Ca^{2+}$ . The  $Na^+$ -free buffer contained 145 mM *N*-methylglucamine to substitute  $Na^+$ . The  $Mg^{2+}$ -free buffer contained no  $Mg^{2+}$ . The high  $K^+$  buffer contained 25 mM  $K^+$ . Cells were placed in each buffer for 5 min before treatment with CRF (42 pM,  $n = 3-5$ ). \*  $P < 0.05$  vs. vehicle control, \*\*  $P < 0.05$  vs. respective vehicle, two-way ANOVA, and Bonferroni's inequality.

$Na^+/Ca^{2+}$  exchanger (Kiang et al., 1992), leading to an increase in the resting  $[Ca^{2+}]_i$ . The reason for the increase resulting from the removal of  $Mg^{2+}$  is not clear. However, CRF still induced the same magnitude of  $[Ca^{2+}]_i$  increase in cells in absence of either cations (Fig. 3).

It has been reported that membrane depolarization can increase  $[Ca^{2+}]_i$  in some cells (Hagiwara, 1983). I therefore sought to determine if the increase in  $[Ca^{2+}]_i$  is caused by a CRF-induced depolarization of the A-431 cell membrane. Cells were first bathed in a buffer containing 25 mM  $K^+$  (normal  $[K^+] = 4.5$  mM), conditions that will depolarize the membrane of sensitive cells. However, this treatment did not change the resting  $[Ca^{2+}]_i$ , and CRF induced the same magnitude of  $[Ca^{2+}]_i$  increase as that measured in cells incubated with normal buffers (Fig. 3). These results indicate that the increase in  $[Ca^{2+}]_i$  stimulated by CRF is not a result of a membrane depolarization.

### 3.2. Effect of $Ca^{2+}$ channel blockers

We sought to determine the role of extracellular  $Ca^{2+}$  in the increase in  $[Ca^{2+}]_i$  stimulated by CRF. The entry of  $Ca^{2+}$  into cells can be blocked by  $Co^{2+}$  or  $La^{3+}$  (inorganic  $Ca^{2+}$  channel blockers) in the external medium (Hagiwara, 1983). Table 1 shows that treatment with either  $Co^{2+}$  or  $La^{3+}$  slightly changed the resting  $[Ca^{2+}]_i$ , but CRF did not increase  $[Ca^{2+}]_i$  in the presence of either blocker. These results reinforce the concept that the increase in  $[Ca^{2+}]_i$  induced by CRF is due to a  $Ca^{2+}$  influx.

Different results were obtained with the organic  $Ca^{2+}$  channel blockers, verapamil (10  $\mu$ M) and nifedipine (10  $\mu$ M). Although these agents by themselves induced a change in the resting  $[Ca^{2+}]_i$ , treat-

ment with CRF in the presence of either verapamil or nifedipine stimulated a significant additional increase in  $[Ca^{2+}]_i$  (Table 1). Much higher concentrations of verapamil and nifedipine (up to 1 mM) also failed to inhibit the CRF-induced increase in  $[Ca^{2+}]_i$  (data not shown). These results indicate that the  $Ca^{2+}$  entry stimulated by CRF does not occur through voltage-gated  $Ca^{2+}$  channels. The data are consistent with the view that A-431 cells are not excitable (Kiang et al., 1992, Moolenaar et al., 1986) and that the  $[Ca^{2+}]_i$  increase is not associated with membrane depolarization.

Because  $Co^{2+}$  and  $La^{3+}$  can function not only to block  $Ca^{2+}$  channels but also to block  $Na^+/Ca^{2+}$  exchange (Trosper and Philipson, 1983; Kaczorowski et al., 1989), it was necessary also to assess the effect of CRF on the  $Na^+/Ca^{2+}$  exchanger. This antiporter system located at the cell membrane translocates  $Ca^{2+}$ , coupled to the movement of  $Na^+$  in the opposite direction. The direction of ion transport across the plasma membrane depends upon the prevailing ionic gradients established by the  $Na^+/K^+$ -ATPase, the  $Na^+/H^+$  antiporter, and  $Na^+$  channels. Cells were treated with 1 mM amiloride or 100  $\mu$ M benzamil, inhibitors of the  $Na^+/Ca^{2+}$  exchanger. Table 2 shows that amiloride and benzamil both increased the resting  $[Ca^{2+}]_i$ , indicating that a  $Na^+/Ca^{2+}$  exchanger is present in these cells. However, CRF treatment still increased  $[Ca^{2+}]_i$  in amiloride- or benzamil-treated cells, excluding the possibility that the  $Na^+/Ca^{2+}$  exchange system is inhibited by CRF.

### 3.3. Effect of $\alpha$ -helical CRF-(9–41)

The increase in  $[Ca^{2+}]_i$  by CRF was inhibited by  $\alpha$ -helical CRF-(9–41), a CRF receptor antagonist (Rivier et al., 1984). The degree of inhibition depended on the concentration of the inhibitor (Fig. 4A), with the median inhibitory concentration ( $IC_{50}$ ) occurring at

Table 1  
Inorganic  $Ca^{2+}$  channel blockers inhibited the CRF-induced increase in  $[Ca^{2+}]_i$

	$[Ca^{2+}]_i$ (nM)	
	Control	CRF
–	57 ± 9	150 ± 20 <sup>a</sup>
$La^{3+}$	63 ± 4	63 ± 5
$Co^{2+}$	21 ± 6 <sup>a</sup>	21 ± 7 <sup>a</sup>
Verapamil	82 ± 27 <sup>a</sup>	215 ± 84 <sup>b</sup>
Nifedipine	99 ± 16 <sup>a</sup>	209 ± 31 <sup>b</sup>

Cells were treated with  $Ca^{2+}$  channel blockers 10  $\mu$ M for 1 min before 42 pM CRF ( $n = 5$ ).

<sup>a</sup>  $P < 0.05$  vs. controls without treatment with  $Ca^{2+}$  channel blockers.

<sup>b</sup>  $P < 0.05$  vs. respective control, two-way ANOVA, and Bonferroni's inequality.

Table 2

Amiloride, benzamil, U-73122, TMB-8, and ryanodine did not inhibit the CRF-induced increase in  $[Ca^{2+}]_i$ .

	Concentration	$[Ca^{2+}]_i$ (nM)	
		Control	CRF
–	–	57 ± 9	150 ± 20 <sup>a</sup>
Amiloride	1 mM	115 ± 10 <sup>a</sup>	226 ± 9 <sup>b</sup>
Benzamil	100 μM	82 ± 5 <sup>a</sup>	167 ± 14 <sup>b</sup>
U-73122	5 μM	173 ± 12 <sup>a</sup>	264 ± 12 <sup>b</sup>
TMB-8	100 μM	114 ± 18 <sup>a</sup>	283 ± 55 <sup>b</sup>
Ryanodine	100 μM	35 ± 7	104 ± 16 <sup>b</sup>

Cells were treated with amiloride, benzamil, U-73122, TMB-8, or ryanodine 1 min prior to CRF (42 pM) ( $n = 4-5$ ).

<sup>a</sup>  $P < 0.05$  vs. control without any treatment.

<sup>b</sup>  $P < 0.05$  vs. respective control, two-way ANOVA, and Bonferroni's inequality.

33 nM and complete inhibition at 1 μM (Fig. 4B). These results suggest that the CRF-induced increase in  $[Ca^{2+}]_i$  is mediated by receptor-operated  $Ca^{2+}$  channels.

If the increase in  $[Ca^{2+}]_i$  induced by CRF were mediated by a receptor that coupled to G proteins to




Fig. 4. Inhibition of the CRF-induced increase in  $[Ca^{2+}]_i$  by CRF antagonist. Cells were treated with CRF antagonist (CRFa) at the indicated concentrations 1 min prior to challenge with 420 pM CRF ( $n = 5$ ). The fluorometer tracings (A) and the sigmoid-curved fit (B) are presented. The calculated median inhibitory concentration was 33 nM.




Fig. 5. Effect of CRF antagonist, pertussis toxin, suramin, and naloxone on the CRF-induced increase in  $[Ca^{2+}]_i$ . Cells were treated with CRF antagonist (CRFa, 100 nM), suramin (SA, 100 μg/ml), naloxone (NX, 50 μM) for 1 min, or pertussis toxin (PTX, 30 ng/ml) for 24 h before challenging with 42 pM CRF ( $n = 3-5$ ). \*  $P < 0.05$  vs. vehicle control, \*\*  $P < 0.05$  vs. respective vehicle, two-way ANOVA, and Bonferroni's inequality.

open  $Ca^{2+}$  channels, treatment with pertussis toxin would also block the increase, because pertussis toxin has been shown to block  $Ca^{2+}$  channels that are stimulated by receptor-linked  $G_k/G_o$  proteins (Gilman, 1987; Lyengar and Birnbaumer, 1987; Spiegel et al., 1988). On the other hand, if increases in  $[Ca^{2+}]_i$  induced by CRF were directly mediated by a receptor coupled to  $Ca^{2+}$  channels, then treatment with pertussis toxin should not inhibit the increase. Cells incubated with 30 ng/ml pertussis toxin for 24 h demonstrated an increase in  $[Ca^{2+}]_i$  of only  $38 \pm 8\%$  ( $n = 5$ ,  $P < 0.05$ , Student  $t$ -test) after treatment with 42 pM CRF, whereas CRF increased  $[Ca^{2+}]_i$   $134 \pm 20\%$  ( $n = 10$ ,  $P < 0.05$ , Student's  $t$ -test) in the absence of pertussis toxin treatment, suggesting that the CRF receptor is coupled to a pertussis toxin-sensitive G protein.

The inhibition by  $\alpha$ -helical CRF-(9–41) was specific because suramin (a purinergic receptor inhibitor) and naloxone (an opiate receptor antagonist) did not inhibit the increase in  $[Ca^{2+}]_i$  induced by CRF (Fig. 5). (Treatment of cells with either suramin or naloxone in the absence of CRF increased the resting  $[Ca^{2+}]_i$ , but the reason for this increase was not understood.) I sought to determine whether  $\alpha$ -helical CRF-(9–41) interfered with agents other than CRF that can stimulate an increase in  $[Ca^{2+}]_i$ . ATP is an agent that has been shown to increase  $Ca^{2+}$  influx in A-431 cells (Gonzales et al., 1989). ATP (100 μM) increased  $[Ca^{2+}]_i$  by  $303 \pm 43\%$  ( $n = 5$ ) in the absence of  $\alpha$ -helical CRF-(9–41). In the presence of  $\alpha$ -helical CRF-(9–41), ATP still increased  $[Ca^{2+}]_i$  by  $232 \pm 56\%$  ( $n = 4$ ), which was not significantly different from the increase observed in the absence of  $\alpha$ -helical CRF-(9–41) ( $P > 0.05$ , Student's  $t$ -test). The results suggest that the CRF-induced increase in  $[Ca^{2+}]_i$  is specifically mediated by CRF receptors.



### 3.4. Effect of CRF on cAMP

CRF at 42 pM for 10 min induced a maximal increase in  $[Ca^{2+}]_i$ . However, this concentration did not increase cellular cAMP content either in the presence or absence of external  $Ca^{2+}$  in the first 10 sec when the increase in  $[Ca^{2+}]_i$  was observed. This would exclude the involvement of second messenger-operated  $Ca^{2+}$  channels activated by cAMP. It is important to note that a 10 min incubation with CRF increased cellular cAMP from  $1.0 \pm 0.2$  pmole/ $10^6$  cells to  $1.4 \pm 0.1$  pmole/ $10^6$  cells ( $n = 3$ ,  $P < 0.05$ , Student's *t*-test). Any future study of the prolonged effect of CRF should therefore consider the involvement of cAMP in any observed increases in  $[Ca^{2+}]_i$ , because a 10 min treatment with 1 mM 8-bromo-cAMP in A-431 cells is capable of increasing  $[Ca^{2+}]_i$  by  $35 \pm 5\%$  (Kiang and McClain, 1993).

### 3.5. Effect of CRF on intracellular $Ca^{2+}$ stores

Three intracellular  $Ca^{2+}$  pools have been identified in A-431 cells:  $InsP_3$ -, monensin-, and ionomycin-sensitive pools (Kiang and Smallridge, unpublished data). My data indicate that the  $InsP_3$ -sensitive  $Ca^{2+}$  pool is not involved in the CRF response, because CRF did not increase  $InsP_3$  within the same time frame (10 s) as that in which the increase in  $[Ca^{2+}]_i$  was observed. An increase in  $InsP_3$  was observed only after a 10 min treatment with CRF (from  $0.37 \pm 0.06\%$  total cpm to  $0.57 \pm 0.07\%$  total cpm,  $n = 3$  for both groups,  $P < 0.05$ , Student's *t*-test). Furthermore, an inhibitor of  $InsP_3$  production, U-73122, did not inhibit the increase in  $[Ca^{2+}]_i$  induced by CRF (Table 2). Two inhibitors of intracellular  $Ca^{2+}$  mobilization, TMB-8 (a general block for  $Ca^{2+}$  stores, Chiou and Malagodi, 1975; Mix et al., 1984; McCoy et al., 1988) or ryanodine (a blocker for non- $InsP_3$ -sensitive  $Ca^{2+}$  stores, see review Tsien, 1990) were tested to determine whether other intracellular pools were associated with the increase in  $[Ca^{2+}]_i$ . Treatment with TMB-8 (100  $\mu$ M) or ryanodine (100  $\mu$ M) should not interfere with an increase in  $[Ca^{2+}]_i$  induced by CRF if the increase were derived primarily from external sources. That was indeed the case. Neither TMB-8 nor ryanodine blocked the increase, which indicates that intracellular  $Ca^{2+}$  stores are not involved in the CRF-induced increase in  $[Ca^{2+}]_i$ .

## 4. Discussion

The resting  $[Ca^{2+}]_i$  in adherent A-431 cells was  $66 \pm 4$  nM. CRF induced an immediate concentration-dependent increase in  $[Ca^{2+}]_i$  with an  $EC_{50}$  of 11 pM. The increase was apparently due to an influx of extra-

cellular  $Ca^{2+}$  because (1) the increase did not occur if  $Ca^{2+}$  was omitted from the buffer, and (2) inorganic  $Ca^{2+}$  channel blockers inhibited the increase. Voltage-gated  $Ca^{2+}$  channels are not involved because organic  $Ca^{2+}$  channel blockers such as verapamil and nifedipine failed to block the increase. This is in agreement with the results of Moolenaar et al. (1986) and this laboratory (Kiang, 1991; Kiang et al., 1992). Changes in resting  $[Ca^{2+}]_i$  in cells treated with  $Ca^{2+}$  channel blockers are probably due to their ability to affect  $H^+$ -sensitive  $Ca^{2+}$  channels (Kiang, 1991).

The increase in  $[Ca^{2+}]_i$  induced by CRF was inhibited by the CRF receptor antagonist,  $\alpha$ -helical CRF-(9–41). The  $IC_{50}$  required to block the activity of CRF (420 pM) was 33 nM. The inhibition was specific because neither suramin nor naloxone inhibited the CRF-induced increase in  $[Ca^{2+}]_i$  and because this CRF receptor antagonist failed to inhibit the increase in  $[Ca^{2+}]_i$  induced by ATP. Treatment with pertussis toxin attenuated the  $[Ca^{2+}]_i$  response to CRF. These results taken together suggest that the  $Ca^{2+}$  channels involved with CRF activity are CRF receptor-operated and coupled to a pertussis toxin-sensitive G protein.

Because  $Ca^{2+}$  influx can be mediated by second messenger-operated  $Ca^{2+}$  channels, increases in  $[Ca^{2+}]_i$  may result from CRF-stimulated increases in cellular cAMP. Previously this laboratory showed that an exogenous application of 1 mM 8-bromo-cAMP did not immediately change resting  $[Ca^{2+}]_i$  in A-431 cells (Kiang et al., 1991), although prolonged incubation with 8-bromo-cAMP led to  $[Ca^{2+}]_i$  increases (Rinaldi et al., 1981; Kiang and McClain, 1993). In the present study, cAMP did not increase during the same period that  $[Ca^{2+}]_i$  increased after CRF treatment. That is, the  $[Ca^{2+}]_i$  increase was immediate, whereas cAMP failed to increase until 10 min., suggesting that second-messenger operated  $Ca^{2+}$  channels are not stimulated by CRF.

Intracellular  $Ca^{2+}$  pools also do not appear to be involved in the CRF-induced increase in  $[Ca^{2+}]_i$ . This view is supported by two observations. First,  $InsP_3$  did not increase during the same period that  $[Ca^{2+}]_i$  increased after CRF treatment. Second, U-73122 (an inhibitor for  $InsP_3$  production), TMB-8 or ryanodine (inhibitors of intracellular  $Ca^{2+}$  mobilization) failed to inhibit the increase.

Polyvalent cations have been reported to block  $Na^+/Ca^{2+}$  exchange (Trosper and Philipson, 1983; Kaczorowski et al., 1989). Such was not the case here because amiloride and benzamil, inhibitors of the  $Na^+/Ca^{2+}$  exchanger, did not inhibit the increase in  $[Ca^{2+}]_i$ . This is supported further by the observation that removal of external  $Na^+$  did not block the CRF effect on  $[Ca^{2+}]_i$ .

The physiological significance of changes in  $[Ca^{2+}]_i$  has been documented in pituitary cells and in hip-

pocampus. It is highly likely that an increase in  $[Ca^{2+}]_i$  stimulated by CRF is a common signal for various properties possessed by CRF. In mouse pituitary AtT-20 cells, the CRF-induced increase in *c-fos* mRNA is  $Ca^{2+}$ -dependent (Boutillier et al., 1991). In dispersed rat anterior pituitary cells 10 nM ovine CRF increased ACTH release. When  $[Ca^{2+}]_i$  was lowered, ACTH release was attenuated (Won and Orth, 1990). This is probably due to the ability of CRF to increase  $[Ca^{2+}]_i$  (Guerineau et al., 1991). In vivo studies show that CRF injected into the dentate gyrus of the hippocampus enhances memory. Nifedipine and verapamil both antagonize the memory-enhancing effect of CRF (Lee and Lin, 1991). In this study, CRF at concentrations between a normal level and a pregnant level induced a moderate increase in  $[Ca^{2+}]_i$  in A-431 cells that was mediated by CRF-receptor operated  $Ca^{2+}$  channels. The apparent contradiction that nifedipine and verapamil antagonized the memory-enhancing effect of CRF in rat's brain (Lee and Lin, 1991) but did not inhibit the CRF-induced increase in  $[Ca^{2+}]_i$  in A-431 cells can be attributed to the different types of cells used in these experiments.

In summary, this paper demonstrates that CRF increased  $[Ca^{2+}]_i$  in nonendocrine cells in a concentration-dependent manner. The increase was blocked by removal of external  $Ca^{2+}$ , treatment with polyvalent cations, pertussis toxin, or treatment with a CRF antagonist. The data suggest that the increase is due to a  $Ca^{2+}$  influx through CRF-receptor mediated  $Ca^{2+}$  channels.

## 5. Acknowledgements

The author thanks Dr. M.C. Lin for cAMP measurement, SPC Lisa Drouin for  $InsP_3$  measurement, and Dr. David E. McClain for his discussion and editorial assistance. This work was supported by the Department of the Army (ILIR ECN 0027 and RAD II STO B). Views presented in this paper are those of the author; no endorsement by the Department of the Army or the Department of Defense has been given or should be inferred.

## 6. References

- Berridge, M.J., 1983, Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides rather than phosphatidylinositol. *Biochem. J.*, 212, 849.
- Boutillier, A.L., P. Sassone-Corsi and J.P. Loeffler, 1991, The protooncogene *c-fos* is induced by corticotropin-releasing factor and stimulates proopiomelanocortin gene transcription in pituitary cells. *Mol. Endocrinol.* 5, 1301.
- Chiou, C.Y. and M.H. Malagodi, 1975, Studies on the mechanism of action of a new  $Ca^{2+}$  antagonist, 8-(*N,N*-diethylamino)octyl-3,4,5-trimethoxybenzoate hydrochloride in smooth and skeletal muscles. *Br. J. Pharmacol.* 53, 279.
- Gilman, A., 1987, G-proteins: transducers of receptor-generated signals. *Annu. Rev. Biochem.* 32, 207.
- Gonzales, F.A., R.G. Alfonso, J.R. Toro and L.A. Heppel, 1989, Receptor specific for certain nucleotides stimulates inositol phosphate metabolism and  $Ca^{2+}$  fluxes in A-431 cells. *J. Cell. Physiol.* 141, 606.
- Gryniewicz, G., M. Poenie and R.Y. Tsien, 1985, A new generation of  $Ca^{2+}$  with greatly improved fluorescence properties. *J. Biol. Chem.* 260, 3440.
- Guerineau, N., J.B. Corcuff, A. Tabarin and P. Mollard, 1991, Spontaneous and corticotropin-releasing factor-induced cytosolic free calcium transients in corticotrophs. *Endocrinology* 129, 409.
- Hagiwara, S., 1983, Membrane potential-dependent ion channels in cell membrane. In: *Phylogenic and Developmental Approaches* (eds. H.Bader, K. Gietzen, J. Rosenthal, R. Rudel and H.U. Wolf), New York: Raven, p. 60.
- Iyengar, R. and L. Birnbaumer, 1987, Signal transduction by G-proteins. In: *ISI Atlas of Science: Pharmacology*, Vol. 1, p. 213.
- Kaczorowski, G.J., L. Costello, J. Dethmers, M.J. Trumble and R.L. Vandlen, 1989, Mechanisms of  $Ca^{2+}$  transport in plasma membrane vesicles prepared from cultured pituitary cells. I. Characterization of  $Na^+$ - $Ca^{2+}$  exchange activity. *J. Biol. Chem.* 259, 9395.
- Kiang, J.G., 1991, Effect of intracellular pH on cytosolic free  $[Ca^{2+}]_i$  in human epidermoid A-431 cells. *Eur. J. Pharmacol.* 207, 287.
- Kiang, J.G. and D.E. McClain, 1993, Effect of heat shock,  $[Ca^{2+}]_i$ , and cAMP on inositol trisphosphate in human epidermoid A-431 cells. *Am. J. Physiol.* 264 (Cell Physiol. 33), C1561.
- Kiang, J.G., M.L. Koenig, and R.C. Smallridge, 1992, Heat shock increases cytosolic free  $Ca^{2+}$  concentration via  $Na^+$ - $Ca^{2+}$  exchange in human epidermoid A 431 cells. *Am. J. Physiol.* 263 (Cell Physiol. 32), C30.
- Kiang, J.G., and E.T. Wei, 1986, CRF-evoked bradycardia in urethane-anesthetized rats is blocked by naloxone. *Peptide* 6, 409.
- Kiang, J.G., E.T. Wei, and K. Fukujama, 1988, In vivo and in vitro inhibition of thermal injury to skin by peptides of the corticotropin superfamily. *Clin. Res.* 36, 120A.
- Kiang, J.G. and E.T. Wei, 1987, Corticotropin-releasing factor inhibits thermal injury. *J. Pharmacol. Exp. Ther.* 243, 517.
- Lee, E.H. and W.R. Lin, 1991, Nifedipine and verapamil block the memory-facilitating effect of corticotropin-releasing factor in rats. *Life Sci.* 48, 1333.
- Lin, M.C., S.K. Beckner and F.J. Darfler, 1985, Characterization of hormone-sensitive Madin-Darby canine kidney cells. *Methods Enzymol.* 109, 360.
- Linton, E.A., D.P. Behan, P.W. Saphier and P.J. Lowry, 1990a, Corticotropin-releasing hormone (CRH)-binding protein: reduction in the adrenocorticotropin-releasing activity of placental but not hypothalamic CRF. *J. Clin. Endocrinol. Metab.* 70, 1574.
- Linton, E.A., C.D. Wolfe, D.P. Behan and P.J. Lowry, 1990b, Circulating corticotropin-releasing factor in pregnancy. *Adv. Exp. Med. Biol.* 274, 147.
- McCoy, C.E., A.M. Selvaggio, E.A. Alexander, and J.H. Schwartz, 1988, Adenosine triphosphate depletion induces a rise in cytosolic free calcium in canine renal epithelial cells. *J. Clin. Invest.* 82, 1326.
- Merchenthaler, I., 1984, Corticotropin-releasing factor (CRF)-like immunoreactivity in the rat central nervous system. Extrahypothalamic distribution. *Peptide* 5 (Suppl. 1), 53.
- Mix, L.L., R.J. Dinerstein, and M.L., Villereal, 1984, Mitogens and melittin stimulate an increase in intracellular free calcium concentration in human fibroblasts. *Biochem. Biophys. Res. Commun.* 119, 69.
- Moolenaar, W.H., R.J. Aerts, L.G.J. Tertoolen and S.W. Delaet, 1986, The epidermal growth factor-induced calcium signal in A-431 cells. *J. Biol. Chem.* 261, 279.
- Petrusz, P., I. Merchenthaler, P. Ordronneau, J.L. Maderdrut, S.

- Vigh and A.V. Shally, 1984, Corticotropin-releasing factor (CRF)-like immunoreactivity in the gastro-entero-pancreatic endocrine system. *Peptides* 5, 71.
- Plotsky, P.M., 1985, Hypophyseotropic regulation of adenohypophyseal adrenocorticotropin secretion. *Fed. Proc.* 44, 207.
- Rivier, J., C. Rivier and W. Vale, 1984, Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. *Science* 224, 889.
- Rinaldi, M.L., C.J. Le Peuch and J.G. Demaille, 1981, The epinephrine-induced activation of the cardiac slow  $\text{Ca}^{2+}$  channel is mediated by the cAMP-dependent phosphorylation of calmodulin, a 23,000  $M_r$  sarcolemmal protein. *FEBS Lett.* 129, 277.
- Serda, S. and E.T. Wei, 1991, Corticotropin-releasing factor inhibits the acute inflammatory response of rat pawskin to cold injury. *Cryobiology* 28, 185.
- Serda, S. and E.T. Wei, 1992, Epinephrine-induced pulmonary edema in rats is inhibited by corticotropin-releasing factor. *Pharmacol. Res.* 26, 85.
- Spiegel, A., A. Carte and M. Brann, 1988, Signal transduction by guanine nucleotide-binding proteins. *Recent Prog. Horm. Res.* 44, 337.
- Trosper, T.L. and K.D. Philipson, 1983, Effects of divalent and trivalent cations on  $\text{Na}^+/\text{Ca}^{2+}$  exchange in cardiac sarcolemmal vesicles. *Biochim. Biophys. Acta* 731, 63.
- Tsien, R.W., 1990, Calcium channels, stores, and oscillations, *Annu. Rev. Cell. Biol.* 6, 715.
- Wei, E.T. and G.C. Gao, 1991, Corticotropin-releasing factor: an inhibitor of vascular leakage in rat skeletal muscle and brain cortex after injury. *Reg. Peptides* 33, 93.
- Wei, E.T. and J.G. Kiang, 1987, Inhibition of protein exudation from the trachea by corticotropin-releasing factor. *Eur. J. Pharmacol.* 140, 63.
- Wei, E.T., J.G. Kiang, J.Q. Tian and K. Fukuyama, 1987, Corticotropin-releasing factor, urotensin I., and sauvagine inhibit thermal injury to skin (Abstract). Paper presented at the IUPHAR meeting, Sydney, Australia, August 24-28.
- Wei, E.T., S. Serda and J.Q. Tian, 1988, Protective actions of corticotropin-releasing factor on thermal injury to rat pawskin. *J. Pharmacol. Exp. Ther.* 247, 1082.
- Wolfe, C.D., S.P. Patel, E.A. Cambell, E.A. Linton, J. Anderson, P.J. Lowry and M.T. Jones, 1988, Plasma corticotropin-releasing factor (CRF) in normal pregnancy. *Br. J. Obstet. Gynecol.* 95, 997.
- Won, J.G. and D.N. Orth, 1990, Roles of intracellular and extracellular calcium in the kinetic profile of adrenocorticotropin secretion by perfused rat anterior pituitary cells. I. Corticotropin-releasing factor stimulation. *Endocrinology* 126, 849.